Central Disorders of Hypersomnolence

xywave jazz narcolepsy cataplexy eds
Sleep Pharmaceuticals Idiopathic Hypersomnia

Jazz Presents Phase 3 Results of Xywav in Adults with Idiopathic Hypersomnia

Jazz Pharmaceuticals plc has announced positive results from the Phase 3 study of XywavTM (calcium, magnesium, potassium, and sodium oxybates) oral solution in adult patients with idiopathic hypersomnia, which will be presented during the Clinical Trials Plenary Session of the 2021 American Academy of Neurology (AAN) Annual Meeting. The presentation will further […]

Sleep Pharmaceuticals Narcolepsy

Promising Data for First New Narcolepsy Drug in Ten Years, Pending Approval

Platform presentation highlights open-label, long-term safety and tolerability results, durability of effect over time in both EDS and cataplexy in patients with narcolepsy Harmony Biosciences, LLC (Harmony) recently presented new data on pitolisant at the 7th International Symposium on Narcolepsy in Beverly, MA. Pitolisant is an investigational product that has […]

WUN Research/Studies

Wake Up Narcolepsy Awards $90,000 To Research

Wake Up Narcolepsy Awards Unrestricted Grants to Stanford And Harvard Narcolepsy Research At the SLEEP 2018 meeting held in early June, Wake Up Narcolepsy awarded Dr. Mignot from Stanford Center for Sleep Sciences and Medicine $45,000 for ongoing research. The funding allows Dr. Mignot to continue his pivotal research into […]